Full Press Release Details
Blog Post
| July 11, 2023
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
Read More
Previous Article
Next Article
Blog Navigation
VANI Positive Sentiment
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
Key Takeaway: Vivani Medical's subsidiary, Cortigent, has released an update on its 5-year early feasibility study for the Orion® Visual Cortical Prosthesis System. This update highlights the progress made in the study, suggesting potential advancements in visual restoration technology. The findings could have significant implications for individuals with vision impairments.
Price reaction · baseline $1.3 (2023-07-10 close) · hit pre-market · clean, no other VANI news in the window
day 0 close · peak
-3.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Cortigent has provided an update on a 5-year feasibility study.
- The Orion® Visual Cortical Prosthesis System shows promise.
- The study reflects ongoing commitment to innovation in visual prosthetics.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~10 mo
Medium dilution risk
Lead asset
Semaglutide
Phase 1 · Obesity & Overweight
Frequently Asked Questions
What is the Orion® Visual Cortical Prosthesis System?
The Orion® Visual Cortical Prosthesis System is a device designed to restore vision.
Who reported the update on the feasibility study?
The update was reported by Cortigent, a subsidiary of Vivani Medical, Inc.
How long is the feasibility study for the Orion system?
The feasibility study for the Orion system spans five years.
What does the update indicate about the study?
The update suggests significant progress in the development of visual restoration technology.